Vancocin Italia Drug Patent Portfolio
Vancocin Italia owns 1 orange book drug protected by 4 US patents Given below is the list of Vancocin Italia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9427402 | Preparation for improving solubility of poorly soluble drug | 29 Sep, 2031 | Active |
| US8530668 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | 21 Jan, 2030 | Active |
| US8889722 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | 29 Jul, 2028 | Active |
| US7601746 | Compounds exhibiting thrombopoietin receptor agonism | 05 Sep, 2024 | Expired |
Latest Legal Activities on Vancocin Italia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vancocin Italia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Withdrawal of Application for PTE
Critical
| 06 May, 2024 | US7601746 |
|
Patent Term Extension Certificate
Critical
| 06 May, 2024 | US8889722 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Feb, 2024 | US9427402 |
| Notice of Final Determination -Election Required | 09 Feb, 2024 | US8889722 |
| Notice of Final Determination -Election Required | 09 Feb, 2024 | US7601746 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US8889722 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US7601746 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2024 | US8889722 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2024 | US7601746 |
|
Email Notification
Critical
| 25 Jan, 2024 | US9427402 |
|
Email Notification
Critical
| 25 Jan, 2024 | US7601746 |
|
Email Notification
Critical
| 25 Jan, 2024 | US8889722 |
|
Email Notification
Critical
| 25 Jan, 2024 | US8530668 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2024 | US8530668 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2024 | US9427402 |
Vancocin Italia's Family Patents
Vancocin Italia Drug List
Given below is the complete list of Vancocin Italia's drugs and the patents protecting them.
1. Mulpleta
Mulpleta is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9427402 | Preparation for improving solubility of poorly soluble drug |
29 Sep, 2031
(6 years from now)
| Active |
| US8530668 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
21 Jan, 2030
(5 years from now)
| Active |
| US8889722 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
29 Jul, 2028
(3 years from now)
| Active |
| US7601746 | Compounds exhibiting thrombopoietin receptor agonism |
05 Sep, 2024
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mulpleta's drug page